Valient Pharmaceuticals

Valient Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments across various therapeutic areas, focusing particularly on unmet medical needs. Valient Pharmaceuticals operates within the pharmaceutical sector, specializing in the development of biopharmaceutical products. The company has its headquarters in Quebec City, Canada. Information on changes in business operations or structure is not provided.

The founder's history and other specifics about leadership are also not mentioned in the available data. Valient Pharmaceuticals offers a diverse range of pharmaceutical and medical products designed to address various health needs across multiple therapeutic areas. Their offerings include treatments for gastrointestinal health, dermatology, vision care, and other specialties, with key products such as Xifaxan® (rifaximin) aimed at managing hepatic encephalopathy and dermatological conditions. These products are targeted towards healthcare professionals, hospitals, and outpatient facilities, ultimately benefiting patients who require effective management of chronic and acute health conditions.

The extensive product portfolio is distributed across the United States, Canada, Europe, and selected international regions. Valient Pharmaceuticals generates revenue primarily through direct sales of their pharmaceutical and medical products to healthcare providers, hospitals, and specialty pharmacies. Their revenue model includes B2B transactions with wholesalers and distributors as well as direct-to-consumer sales through healthcare channels, involving negotiated pricing for bulk purchases of flagship products such as Xifaxan®. This sales structure helps create consistent revenue streams while accommodating diverse client needs.

Valient Pharmaceuticals is focused on expanding its portfolio with new product launches aimed at addressing additional health needs. Specifics on upcoming products or release dates are not available. The company is also exploring opportunities for geographic expansion into new markets, although no specific regions or timelines are provided. Current funding will be strategically utilized to support ongoing research and development initiatives, but detailed information on the use of funds is not disclosed.